Neuro disorders represent a broad spectrum of conditions affecting the central and peripheral nervous systems, including neurodegenerative, neuroinflammatory, and neurodevelopmental diseases. This study presents a comprehensive review of the pathophysiology, clinical presentations, and diagnostic frameworks of major neuro disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. We also examine recent advances in neuroimaging, genetic biomarkers, and novel therapeutic strategies. An integrative approach combining clinical, molecular, and technological perspectives is essential for improving diagnostic accuracy and patient outcomes. This paper outlines a multidisciplinary framework to enhance understanding and promote translational research in the field of neurology.

Neuro disorders are among the leading causes of disability and mortality worldwide, significantly burdening patients, caregivers, and healthcare systems. The increasing global prevalence of disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), epilepsy, and multiple sclerosis (MS) is closely associated with aging populations, lifestyle changes, and genetic predispositions. Although substantial progress has been made in understanding the clinical and molecular mechanisms of these conditions, challenges persist in early diagnosis, effective treatment, and long-term management. This study provides a critical review of the neurobiological underpinnings, diagnostic approaches, and emerging interventions for major neuro disorders. We emphasize the need for personalized medicine, integration of biomarker-based diagnostics, and innovations in pharmacological and non-pharmacological therapies.

This study is a narrative review compiled from multiple databases including PubMed, Scopus, and Google Scholar. Articles published between 2010 and 2024 were screened for inclusion. Key search terms included “neuro disorders,” “neurodegeneration,” “biomarkers in neurology,” “neuroinflammation,” “genetics of Alzheimer’s,” and “emerging neurotherapies.” Peer-reviewed original research articles, meta-analyses, and systematic reviews were prioritized.

Selection criteria included:

• Relevance to human neurological disorders
• Focus on pathophysiology, diagnosis, or therapy
• English language publication

Thematic synthesis was applied to categorize findings into sections on neurobiology, diagnostics, and treatments.

The review identified consistent themes across major neuro disorders:

1. Neurodegeneration and Proteinopathies;
   Diseases such as AD and PD show characteristic protein misfolding (e.g., beta-amyloid, tau, and alpha-synuclein), leading to synaptic dysfunction and neuronal death.
2. Inflammatory Mechanisms:
   MS and other autoimmune neuro disorders exhibit demyelination and immune-mediated neuronal injury. Chronic inflammation is increasingly recognized in AD and PD as well.
3. Genetic and Epigenetic Markers:
   Variants such as APOE-e4 (Alzheimer’s) and LRRK2 (Parkinson’s) are strongly associated with disease risk. Epigenetic changes influence gene expression and disease progression.
4. Diagnostic Advances:
   Neuroimaging (fMRI, PET), cerebrospinal fluid biomarkers (tau, Aβ42), and blood-based markers have improved early diagnosis and disease monitoring.
5. Therapeutic Approaches:
   • Pharmacological: Cholinesterase inhibitors in AD, dopamine agonists in PD, immunomodulators in MS.
   • Non-pharmacological: Cognitive rehabilitation, deep brain stimulation, and lifestyle interventions are gaining traction.

The pathophysiology of neuro disorders reflects a convergence of genetic, environmental, and inflammatory factors. A notable challenge is the heterogeneity in disease presentation and progression. For example, while Alzheimer’s is traditionally considered a disease of memory, emerging subtypes show prominent behavioral or language impairments. Multimodal diagnostics that combine neuroimaging, fluid biomarkers, and neuropsychological testing offer the best predictive value. However, accessibility remains a challenge in resource-limited settings. The integration of artificial intelligence in imaging analysis and predictive modeling may address this gap. Therapeutically, disease-modifying treatments remain limited. The recent approval of anti-amyloid therapies in AD has sparked both optimism and debate due to modest clinical benefit and potential side effects. Meanwhile, neuroprotective and regenerative therapies are in various stages of clinical trials. A key future direction involves targeting neuroinflammation, mitochondrial dysfunction, and synaptic repair using multi-target pharmacological agents and stem cell-based therapies.

Neuro disorders are complex and multifactorial, demanding an integrative approach that encompasses molecular biology, clinical neurology, and innovative technology. While significant strides have been made in understanding their mechanisms and improving diagnostics, effective treatments that halt or reverse disease progression are still evolving. Collaborative research, personalized therapeutic strategies, and broader access to diagnostic tools will be pivotal in transforming the clinical management of neuro disorders.